Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Omeros reports on phase II trial of PPARgamma agonist in heroin-dependent subjects

Nov. 3, 2016

Opiant Pharmaceuticals licenses heroin vaccine from WRAIR and NIDA

Nov. 3, 2016

Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors

Oct. 31, 2016

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Oct. 20, 2016

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Oct. 20, 2016

Addex initiates study of ADX-88178 in nonhuman primate model of cocaine addiction

Oct. 11, 2016

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Aug. 19, 2016

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Aug. 17, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...